Repression of Interferon Regulatory Factor-4(Irf4)hyperactivation Restricts Murine Lupus

Dear Editor, Hyperactivation of the type Ⅰ interferon(IFN)signature has been observed in several systemic autoimmune conditions,and the type Ⅰ IFN receptor antagonist Saphnelo(anifrolumab-fnia)has been approved in 2021 by the Food and Drug Administration(FDA)in the US.The launch of Saphnelo marked the only new treatment approved for systemic lupus erythematosus(SLE)in more than 10 years.